Liquid biopsy for detection of actionable oncogenic mutations in human cancers and electric field induced release and measurement liquid biopsy (eLB).
Liquid biopsy for detection of actionable oncogenic mutations in human cancers and electric field induced release and measurement liquid biopsy (eLB).
复制标题
DOI：
10.1039/c5an01863c
复制
发表时间：
2016-01-21
期刊：
影响因子：
--
通讯作者：
Wong D
中科院分区：
文献类型：
--
作者：
Tu M;Chia D;Wei F;Wong D
由EGFR和KRAS等关键癌症基因突变引起的致癌激活经常与人类癌症有关。针对人类癌症中特定的癌基因突变进行分子靶向治疗是抗癌药物治疗的主要途径。此外，癌基因突变的进行性发展会导致耐药性。因此，检测和持续监测关键的可操作致癌基因突变的能力对于指导使用靶向分子治疗来改善癌症患者的长期临床结果是重要的。目前的癌基因突变检测是基于通过手术切除或活检对癌组织进行直接采样。最近发现，在癌症患者的循环体液中可以检测到致癌基因突变。这一研究领域被称为液体活检，允许采用一种侵入性较小的方法来评估患者的致癌基因突变情况。本文将回顾用于评估来自生物体液样本的致癌突变的分析策略。临床应用也将被讨论。
Oncogenic activations by mutations in key cancer genes such as EGFR and KRAS are frequently associated with human cancers. Molecular targeting of specific oncogenic mutations in human cancer is a major therapeutic inroad for anti-cancer drug therapy. In addition, progressive developments of oncogene mutations lead to drug resistance. Therefore, the ability to detect and continuously monitor key actionable oncogenic mutations is important to guide the use of targeted molecular therapies to improve long-term clinical outcomes in cancer patients. Current oncogenic mutation detection is based on direct sampling of cancer tissue by surgical resection or biopsy. Oncogenic mutations were recently shown to be detectable in circulating bodily fluids of cancer patients. This field of investigation, termed liquid biopsy, permits a less invasive means of assessing the oncogenic mutation profile of a patient. This paper will review the analytical strategies used to assess oncogenic mutations from biofluid samples. Clinical applications will also be discussed.